Back to top
more

Inogen (INGN)

(Real Time Quote from BATS)

$9.43 USD

9.43
1,907

-0.19 (-1.98%)

Updated Oct 2, 2024 10:00 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Hologic (HOLX) Product Pipeline Strong, Competition Rife

by Zacks Equity Research

On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.

    NuVasive (NUVA) Grappling with Odds: Should You Dump Stock?

    by Zacks Equity Research

    On Jun 28, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA), a major player in the global spine market.

      CryoLife Hits a 52-Week High: What's Driving the Stock?

      by Zacks Equity Research

      Leading medical device and tissue processing company, CryoLife, Inc. (CRY) rallied to a new 52-week high of $20.20 on Jun 27, eventually closing a little lower at $19.65.

        Ensign Group (ENSG) Acquires Facilities in Texas & Wisconsin

        by Zacks Equity Research

        The Ensign Group, Inc. (ENSG) recently announced that it acquired the real estate and operations of two assisted living facilities in Texas and three assisted living facilities in Wisconsin.

          Express Scripts Gains from Increased Generic Utilization

          by Zacks Equity Research

          On Jun 27, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).

            Varian Rides on Oncology and Proton Therapy Businesses

            by Zacks Equity Research

            On Jun 27, we issued an updated research report on Palo Alto, CA-based Varian Medical Systems Inc. (VAR).

              What Drove Becton, Dickinson (BDX) to a New 52-Week High?

              by Zacks Equity Research

              Share price of Becton, Dickinson and Company (BDX) , based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $196.01 on Jun 27.

                Quintiles' (Q) OCE Software to Simplify Commercial Functions

                by Zacks Equity Research

                QuintilesIMS (Q) announced the general availability of Orchestrated Customer Engagement (OCE) software to streamline pharmaceutical commercial functions.

                  Medtronic (MDT) Partners with Aetna for Type 1 & 2 Diabetes

                  by Zacks Equity Research

                  Medtronic plc (MDT) recently inked a new 'outcomes-based' collaboration with Aetna (AET) for type 1 and type 2 diabetes patients who are on doses of multiple daily insulin injections.

                    Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test

                    by Zacks Equity Research

                    Thermo Fisher Scientific Inc. (TMO), a leading scientific instrument maker, recently received premarket approval (PMA) from the U.S. FDA for its Oncomine Dx Target Test.

                      Penumbra (PEN) at 52-Week High: What's Driving the Stock?

                      by Zacks Equity Research

                      Share price of Penumbra, Inc. (PEN), headquartered in Alameda, CA, scaled a new 52-week high of $91 on Jun 26, eventually closing a little lower at $86.95.

                        Medidata (MDSO), inVentiv Enter Into Multi-Year Partnership

                        by Zacks Equity Research

                        Medidata Solutions Inc. (MDSO) recently announced that it has entered into a multi-year partnership with inVentiv Health, a leading biopharmaceutical professional services company.

                          ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System

                          by Zacks Equity Research

                          Medical technology company, ConforMIS, Inc. (CFMS) recently announced the receipt of FDA 510(k) clearance for its primary iTotal Hip replacement system.

                            Merit Medical Embosphere Gets FDA de novo Classification

                            by Zacks Equity Research

                            Merit Medical Systems, Inc. (MMSI) recently announced the receipt of 513(f)(2) (de novo) classification for Embosphere Microspheres from the FDA to expand its indication in the prostatic artery embolization (PAE) space.

                              Quest Diagnostics Enhances Blueprint for Athletes Service

                              by Zacks Equity Research

                              Quest Diagnostics Inc. (DGX), a global provider of clinical lab services, recently expanded its biomarker testing service known as Blueprint for Athletes.

                                Why Investors Should Buy Align Technology (ALGN) Right Now

                                by Zacks Equity Research

                                Align Technology, Inc. (ALGN), the designer and manufacturer of Invisalign System, has rallied 51.9% over the last six months, ahead of the S&P 500's 7.9% gain.

                                  Cooper Companies (COO) Hits 52-Week High on Solid Prospects

                                  by Zacks Equity Research

                                  The Cooper Companies (COO) rallied to a new 52-week high of $247.80 on Jun 22, closing a tad lower at $245.06.

                                    Evolent Health (EVH) Prices 4.5M Follow-On Share Offering

                                    by Zacks Equity Research

                                    Evolent Health, Inc. (EVH) recently announced the pricing of its follow-on public offering of 4.5 million shares of Class A common stock at $25.90 per share.

                                      Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now

                                      by Zacks Equity Research

                                      Thermo Fisher Scientific, Inc. (TMO) has rallied 13.5% over the past three months, ahead of the S&P 500's mere 4.3% gain.

                                        Here's Why Henry Schein is Worth Adding to Your Portfolio

                                        by Zacks Equity Research

                                        Over the last six months, Henry Schein Inc. (HSIC) was consistently trading ahead of the S&P 500 Index.

                                          PRA Health Hits a 52-Week High on Strategic Acquisitions

                                          by Zacks Equity Research

                                          Leading global contract research organization PRA Health Sciences (PRAH) rallied to a new 52-week high of $78.30 on Jun 21, closing a little lower at $77.21.

                                            Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How

                                            by Zacks Equity Research

                                            Bio-Rad Laboratories, Inc. (BIO) has rallied 12.9% over the last three months, ahead of the S&P 500's 4.3% gain.

                                              Luminex (LMNX) Banks on Portfolio Strength, View Impressive

                                              by Zacks Equity Research

                                              On Jun 21, we issued an updated research report on Austin, TX-based Luminex Corp (LMNX) -- a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry.

                                                Why Investors Should Buy Edwards Lifesciences (EW) Right Now

                                                by Zacks Equity Research

                                                Leading CA-based medical equipment major Edwards Lifesciences Corporation (EW) is currently on a healthy growth trajectory.

                                                  Why Quest Diagnostics (DGX) is a Suitable Pick for Investors

                                                  by Zacks Equity Research

                                                  Madison, NJ-based Quest Diagnostics, Inc. (DGX), a provider of commercial laboratory services, has been on a growth trajectory of late.